Evidence map›Paper›PMID 18321879›Full record

Trial reportClinical and vaccine immunology : CVI2008

Improved performance of enzyme-linked immunosorbent assays and the effect of human immunodeficiency virus coinfection on the serologic detection of herpes simplex virus type 2 in Rakai, Uganda.

Jordyn L Gamiel, Aaron A R Tobian, Oliver B Laeyendecker, Steven J Reynolds, Rhoda Ashley Morrow, David Serwadda, Ronald H Gray, Thomas C Quinn

Open access · diamondAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Clinical and vaccine immunology : CVI, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 2 pooled it
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 2 syntheses or guidelines pooled it, 53 citations in OpenAlex.

  1. 2024 European guidelines for the management of genital herpes.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025
    Guideline
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Jordyn L GamielDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Aaron A R Tobian
Oliver B Laeyendecker
Steven J Reynolds
Rhoda Ashley Morrow
David Serwadda
Ronald H Gray
Thomas C Quinn
Johns Hopkins Medicine · USNational Institute of Allergy and Infectious Diseases · USUniversity of Washington · USJohns Hopkins University · USMakerere University · UG

Funding

International Center for Excellence in Research (ICER) in Uganda: Impact of ARVsZIAAI001040 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI REYNOLDS, STEVEN · 2009 to 2025
$23.5M
HIV Prevention Trials Network: Network LaboratoryU01AI068613 · NIAID · JOHNS HOPKINS UNIVERSITY · PI ESHLEMAN, SUSAN H · 2006 to 2010
$16.5M
International Studies of the Acquired Immune Deficiency Syndrome (AIDS)ZIAAI000361 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI REDD, ANDREW · 2009 to 2025
$15.8M
Immunopathogenesis Of Chlamydia trachomatis InfectionZIAAI000358 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI QUINN, THOMAS · 2009 to 2022
$7.0M
Intramural NIH HHS Z99 AI999999NIAID NIH HHS U01 AI068613
6 · The paper itself

Abstract

Ugandan subjects (820) were tested by Focus HerpeSelect enzyme-linked immunosorbent assay (ELISA), Kalon herpes simplex virus type 2 ELISA, and BioKit rapid test, and the results were compared to those of Western blotting. Higher-than-standard-index cutoff values gave optimal sensitivity and specificity. Kalon ELISA was the optimal assay when an index value of 1.5 was used (sensitivity, 91.7%; specificity, 92.4%).

Indexed as

Reagent Kits, DiagnosticAdolescentAdultAntibodies, ViralEnzyme-Linked Immunosorbent AssayFemaleHerpes GenitalisHerpesvirus 2, HumanHIVHIV SeropositivityHumansMaleSensitivity and SpecificityUgandaAntibodies, ViralReagent Kits, Diagnostic

Identifiers

PMID18321879
PMCPMC2394849
OpenAlexW2116278834

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.